BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022.
| Conference Call/Webcast Information: | |
| Date: | Tuesday, November 8, 2022 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Listen-Only Audio Webcast: | https://edge.media-server.com/mmc/p/s4tct434 |
| Live Call Participant: | Registration Link |
To participate in the live call, please register using the following link (also noted above) to receive dial-in details and a unique PIN code: Register and receive dial-in details. The audio webcast will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com and posted for replay following the event. The above-listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ: XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
